Contributions of Positron Emission Tomography to elucidating the pathogenesis of Idiopathic Parkinsonism and Dopa Responsive Dystonia
- 1 January 1997
- book chapter
- Published by Springer Nature
- Vol. 50, 47-52
- https://doi.org/10.1007/978-3-7091-6842-4_6
Abstract
The metabolic mapping of brain activity, using PET, confirms the conventional wisdom of neurophysiology. In studies of pathophysiology, PET has yielded evidence that has generated new hypotheses. Progression of the lesion detectable with fluorodopa, in human subjects exposed to MPTP, raises the possibility of a transient environmental event being a cause of progressive neurodegeneration. Studies with fluorodopa in Idiopathic Parkinsonism indicate that the rate of loss of neurons is faster initially, and then tends to approach the normal age-related decline. In dopa responsive dystonia, the finding of normal fluorodopa PET led to the prediction that the lesion would be functional rather than anatomical; this has been confirmed by the identification of a defect in dopamine synthesis in this disorder. Filally, new PET ligands show promise for future studies designed to unravel the pathogenesis of diseases involving the basal ganglia.Keywords
This publication has 18 references indexed in Scilit:
- Permanent hemiparesis due to partial status epilepticusNeurology, 1995
- Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I geneNature Genetics, 1994
- Clinical observations on the rate of progression of idiopathic parkinsonismBrain, 1994
- Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indicesAnnals of Neurology, 1993
- Functional imaging in relation to parkinsonian syndromesJournal of the Neurological Sciences, 1993
- Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomographyAnnals of Neurology, 1992
- Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Cortical glucose metabolism in parkinson's and alzheimer's diseaseJournal of Neuroscience Research, 1990
- The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studiesMovement Disorders, 1990
- Cerebral Glucose Metabolism in Parkinson’s DiseaseCanadian Journal of Neurological Sciences, 1984